Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. 2014

Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
2° Neurology, Department of Medical Biotechnology and Translational Medicine, Milan University, Humanitas Clinical and Research Centre, Rozzano, Milan, Italy.

BACKGROUND Increased titres of serum IgM antibodies to GM1 ganglioside are often associated with multifocal motor neuropathy (MMN). Testing for IgM antibodies to other antigens including GM2, the mixture of GM1 and galactocerebroside (GM1/GalC) and the disulfated heparin disaccharide NS6S were reported to increase the sensitivity of antibody testing in MMN even if it is unclear whether the specificity and positive (PPV) or negative predictive value (NPV) for MMN were also affected. METHODS We measured IgM antibodies to GM1, GM2, galactocerebroside, GM1/GalC and NS6S in 40 consecutive patients with MMN and 142 controls with other neuropathies or related diseases and compared their sensitivity, specificity and PPV for MMN. RESULTS With the only exception of anti-GM2 and, partially, anti-NS6S antibodies, IgM antibodies to the antigens tested were more frequent in MMN than in controls. Increased titres of anti-GM1 IgM were found in 48% of MMN patients with a specificity of 93% and PPV for MMN of 66%. Anti-GM1/GalC antibodies were present in all anti-GM1 positive MMN patients and in 11 additional patients (28%) with MMN raising the sensitivity of antibody testing to 75%. The specificity (85%) and PPV (59%) for MMN was, however, moderately reduced compared to anti-GM1 IgM, even if they rose with increasing anti-GM1/GalC titres. IgM antibodies to GM2, NS6S and galactocerebroside were found in 8%, 23% and 60% of MMN patients but had a low specificity and PPV for MMN. CONCLUSIONS Testing for anti-GM1/GalC IgM significantly increased the sensitivity of antibody testing in MMN compared to anti-GM1 alone (p=0.021) and may represent a preferred option for GM1 reactivity testing in MMN.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D011115 Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance. Polyneuropathy, Acquired,Polyneuropathy, Critical Illness,Polyneuropathy, Familial,Polyneuropathy, Inherited,Polyneuropathy, Motor,Acquired Polyneuropathies,Acquired Polyneuropathy,Critical Illness Polyneuropathies,Critical Illness Polyneuropathy,Familial Polyneuropathies,Familial Polyneuropathy,Inherited Polyneuropathies,Inherited Polyneuropathy,Motor Polyneuropathies,Motor Polyneuropathy,Polyneuropathies, Acquired,Polyneuropathies, Critical Illness,Polyneuropathies, Familial,Polyneuropathies, Inherited,Polyneuropathies, Motor,Polyneuropathy
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D005677 G(M1) Ganglioside A specific monosialoganglioside that accumulates abnormally within the nervous system due to a deficiency of GM1-b-galactosidase, resulting in GM1 gangliosidosis. GM1 Ganglioside,Monosialosyl Tetraglycosyl Ceramide,GM1a Monosialoganglioside,Ceramide, Monosialosyl Tetraglycosyl,Ganglioside, GM1,Monosialoganglioside, GM1a,Tetraglycosyl Ceramide, Monosialosyl
D005699 Galactosylceramides Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy. Galactocerebrosides,Galactosyl Ceramide,Galactosyl Ceramides,Galactosylceramide,Ceramide, Galactosyl,Ceramides, Galactosyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity

Related Publications

Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
November 2010, Neurology,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
May 2015, Journal of neurology, neurosurgery, and psychiatry,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
July 2014, Journal of neurology, neurosurgery, and psychiatry,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
November 1990, Neurology,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
January 2015, Journal of neuroimmunology,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
November 1997, Neurology,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
January 2011, Journal of neurology, neurosurgery, and psychiatry,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
June 2009, Journal of neurology, neurosurgery, and psychiatry,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
March 2022, Cureus,
Eduardo Nobile-Orazio, and Claudia Giannotta, and Lucile Musset, and Paolo Messina, and Jean-Marc Léger
May 1996, Revue neurologique,
Copied contents to your clipboard!